Skip to main content
. 2014 Jul 23;25(10):1941–1948. doi: 10.1093/annonc/mdu269

Figure 1.

Figure 1.

Forest plots of (A) progression-free survival, and (B) overall survival by biomarker subgroups. Patients who did not consent to biomarker analyses, or where there was no suitable tumor sample available, or where the sample was of insufficient quality, or where a sample was unevaluable were categorized as biomarker status unknown.